HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4843-4856

  Bart, Pierre Alexandre ^a,b,i   Huang, Yunda ^c,i   Karuna, Shelly T ^c,i   Chappuis, Samuel ^a,i   Gaillard, Julien ^a   Kochar, Nidhi ^c,i   Shen, Xiaoying ^d   Allen, Mary A ^e   Ding, Song ^b   Hural, John ^c,i   Liao, Hua Xin ^d   Haynes, Barton F ^d   Graham, Barney S ^e   Gilbert, Peter B ^c,i   McElrath, M Juliana ^c,f,g,i   Montefiori, David C ^d,i   Tomaras, Georgia D ^d,i   Pantaleo, Giuseppe ^a,h,i   Frahm, Nicole ^c,f,i  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EuroVacc Foundation   (Switzerland)

^c Fred Hutchinson Cancer Research Center   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h Swiss Vaccine Research Institute   (Switzerland)

ⁱ NIAID HIV Vaccine Trials Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; NEF PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; POL PROTEIN; RECOMBINANT VACCINE; PROTEIN BINDING; VIRUS ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; FEMALE; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT RESPONSE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS STRAIN; YOUNG ADULT; BLOOD; CELL CULTURE; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY;

ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; PROTEIN BINDING; VACCINATION; YOUNG ADULT;

EID: 84908632066     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75894     Document Type: Article

References (54)

1. (UNAIDS) JUNPoHA. WHO Library Cataloguing-in- Publication Data. 2nd ed. Geneva, Switzerland; 2012.
2. Tan WG, et al. Comparative analysis of simian immunodeficiency virus Gag-specific effector and memory CD8(+) T cells induced by different adenovirus vectors. J Virol. 2013;87(3):1359-1372.
3. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo- controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-1893.
4. Barouch DH, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013;207(2):248-256.
5. Churchyard GJ, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6(8):e21225.
6. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
7. Keefer MC, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral- vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine. 2011;29(10):1948-1958.
8. Egan MA, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis. 1995;171(6):1623-1627.
9. Harari A, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008;205(1):63-77.
10. Goepfert PA, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 viruslike particles. J Infect Dis. 2011;203(5):610-619.
11. Bart PA, et al. EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine. 2008;26(25):3153-3161.
12. McCormack S, et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008;26(25):3162-3174.
13. Hayes P, et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus- HIV subtype C vaccine boost in healthy adults. Clin Vaccine Immunol. 2013;20(3):397-408.
14. Priddy FH, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46(11):1769-1781.
15. Frahm N, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122(1):359-367.
16. Diaz-Montero CM, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013;11:62.
17. Casimiro DR, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication- defective adenovirus and poxvirus vaccine vectors. J Virol. 2004;78(20):11434-11438.
18. Betts G, et al. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLoS One. 2012;7(12):e50447.
19. Ratto-Kim S, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One. 2012;7(9):e45840.
20. Barouch DH, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89-93.
21. Peiperl L, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS One. 2010;5(10):e13579.
22. Hammer SM, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083-2092.
23. Sin JI, Bagarazzi M, Pachuk C, Weiner DB. DNA priming-protein boosting enhances both antigen- Specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol. 1999;18(10):771-779.
24. + T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine. 2003;21(31):4555-4564.
25. Harari A, et al. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol. 2012;42(11):3038-3048.
26. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-1286.
27. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413-444.
28. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346-351.
29. Zolla-Pazner S, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9(2):e87572.
30. Tomaras GD, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA. 2013;110(22):9019-9024.
31. Janes H, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis. 2013;208(8):1231-1239.
32. De Rosa SC, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol. 2011;187(6):3391-3401.
33. Aste-Amezaga M, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther. 2004;15(3):293-304.
34. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
35. Bull M, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods. 2007;322(1-2):57-69.
36. Tomaras GD, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82(24):12449-12463.
37. Tomaras GD, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011;85(21):11502-11519.
38. Gottardo R, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013;8(9):e75665.
39. Seaman MS, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439-1452.
40. Li M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16):10108-10125.
41. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;Chapter 12:Unit 12.11.
42. Edmonds TG, et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology. 2010;408(1):1-13.
43. McLinden RJ, et al. Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS One. 2013;8(11):e77756.
44. Sarzotti-Kelsoe M, et al. Optimization validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409C:131-146.
45. Sarzotti-Kelsoe M, et al. Optimization validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods. 2014;409:147-160.
46. Li F, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine. 2006;24(47-48):6893-6904.
47. Horton H, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007;323(1):39-54.
48. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat. 1998;52(17):119-126.
49. Chochran WG. Some methods for strengthening the common chi-squared tests. Biometrics. 1954;10(4):417-451.
50. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11(3):375-386.
51. Jonckheere AR. A distribution-free k-sample test again ordered alternatives. Biometrika. 1954;41:133-145.
52. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6(2):65-70.
53. Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous evaluation of the magnitude and breadth of a left and right censored multivariate response, with application to HIV vaccine development. Stat Biopharm Res. 2009;1(1):81-91.
54. Montefiori DC, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206(3):431-441.